RBC Capital Sees Mixed Q3 for Krystal Biotech as Vyjuvek Beats but Pipeline Readouts Slip

RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.